After closing a private placement to raise $1.56 million towards buying a 25% stake in a new greenhouse earlier in the week, British Columbia-based cannabis company Veritas Pharma Inc. (CSE: VRT) is already announcing another major project.
In a press release issued today, Veritas revealed human trials are set to begin in Puerto Rico for the company’s new CTL-X cannabis strain mix.
The strain has undergone pre-clinical trial testing for the past two years at the University of British Columbia through Veritas’ research subsidiary Cannevert Therapeutics Ltd.
Human trials for the acute pain management strain will be handled in San Juan, Puerto Rico next month with involvement by the Fundación de Investigación (FDI) and the Institute For Medical Cannabis.
While the testing facility and equipment are ready, Veritas is currently awaiting final approval from Puerto Rico’s Department of Health before bringing in human subjects. Veritas Medical Director Scott Alexander commented
... read more at: https://grizzle.com/veritas-pharma-pain-management/